Pfizer

pfizer.com

Pfizer is a leading research-based biopharmaceutical company. We apply science and our global resources to deliver innovative therapies that extend and significantly improve lives. We make medicines and vaccines that help people when they are sick and prevent them from getting sick in the first place, as well as some of the world’s best-known consumer healthcare brands. Every day, our colleagues work in developed and emerging markets to treat, cure and eradicate life-threatening conditions and challenge some of the most feared diseases of our time. Pfizer also collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

National Medtech & Biotech Summit 2024

Conference

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

Related News

PFIZER'S RECORD FINE FOR PHARMACEUTICAL FUNNY BUSINESS IS NO LAUGHING MATTER

Pfzier | December 07, 2016

An £84.2m record fine from the Competition & Markets Authority for pharmaceutical funny business is no laughing matter, even to a giant of the industry like Pfizer. It’ll take more than a few bottles of its signature Viagra to pay that sort of sum, but pay it Pfizer should....

PFIZER FINED FOR HIKING DRUG PRICE IN UK

Pfizer | December 12, 2016

The latest setback for the global biopharmaceutical company, which engages in the manufacture of vaccines and injectable biologic medicines, came last week Wednesday in Britain. The anti-trust regulators imposed a record fine of US$107 million (£84.2 million) on Pfizer for overcharging the National Health Service (NHS) for an epilepsy treatment....

PFIZER WINS QUICK REWARD FROM BUYOUT OF ANACOR WITH APPROVAL OF ECZEMA DRUG EXPECTED TO BE BLOCKBUSTER

Pfizer | December 14, 2016

Score a big win for Pfizer and its $4.5 billion buyout of Anacor Pharmaceuticals. The FDA Wednesday approved Anacor's eczema treatment that is projected to be a $2 billion blockbuster. The FDA approved Eucrisa (crisaborole) ointment to treat mild to moderate atopic dermatitis, better know as eczema, in patients two years and older. The condition results in red, scaly and extremely itchy crusted bumps....

BETTER BUY: PFIZER INC. VS. MERCK

Pfizer | December 14, 2016

This year is turning out quite differently for two of the biggest pharmaceutical companies. Pfizer's (NYSE:PFE) stock is barely above where it started at the beginning of 2016. Merck's (NYSE:MRK) shares, though, are up nearly 20% for the year. But which of these two drug stocks is the better pick for investors now? Here's how Pfizer and Merck compare....